Cytisine versus nicotine for smoking cessation

New England Journal of Medicine

Volumn 371, Issue 25, 2014, Pages 2353-2362

  Walker, Natalie ^a   Howe, Colin ^a   Glover, Marewa ^a   McRobbie, Hayden ^c   Barnes, Joanne ^a   Nosa, Vili ^a   Parag, Varsha ^a   Bassett, Bruce ^b   Bullen, Christopher ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Quit Group   (New Zealand)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTISINE; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; ALKALOID; AZOCINE DERIVATIVE; QUINOLIZINE DERIVATIVE;

ADULT; ARTICLE; BEHAVIOR THERAPY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTIVATION; NAUSEA; NEW ZEALAND; NICOTINE REPLACEMENT THERAPY; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SEX DIFFERENCE; SLEEP DISORDER; SMOKING CESSATION; TELETHERAPY; TOBACCO DEPENDENCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; TOBACCO USE DISORDER; TREATMENT OUTCOME;

ADULT; ALKALOIDS; AZOCINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NICOTINE; QUINOLIZINES; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84919341448     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1407764     Document Type: Article

References (34)

1. Webb C. Checklist of dicotyledons naturalised in New Zealand. NZ J Bot 1980; 18: 463-72 (http://www.tandfonline.com/toc/tnzb20/18/4#.VHzQ6snDXM0)
2. Godley E. Introducing Kowhai. Styx report. Christchurch, New Zealand: Landcare Research, 2006.
3. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48: 3474-7.
4. Jeong S-H, Newcombe D, Sheridan J, Tingle M. Pharmacokinetics of cytisine, an α4 β2 nicotinic receptor partial agonist, in healthy smokers following a single dose. Drug Test Anal 2014 September 17 (Epub ahead of print).
5. Tutka P, Zatoński W. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep 2006; 58: 777-98.
6. Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 2006; 166: 1553-9.
7. Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax 2013; 68: 1037-42.
8. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011; 2: CD006103.
9. McRobbie H, Hajek P, Bullen C, Feigin V. Rapid review of non-NHS treatments for smoking cessation. London: National Institute of Health and Care Excellence, 2006 (http://www.nice.org .uk/guidance/ph10/resources/evidence-review-nonnhstreatments2).
10. Aveyard P, West R. Cytisine and the failure to market and regulate for human health. Thorax 2013; 68: 989.
11. Prochaska JJ, Das S, Benowitz NL. Cytisine, the world's oldest smoking cessation aid. BMJ 2013; 347: f5198.
12. Stapleton JA. The case for licensing cytosine now for smoking cessation is overwhelming. BMJ 2013; 347: f5736.
13. Stapleton JA, West R. A direct method and ICER tables for the estimation of the cost-effectiveness of smoking cessation interventions in general populations: application to a new cytisine trial and other examples. Nicotine Tob Res 2012; 14: 463-71.
14. Walker N, Howe C, Bullen C, et al. Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. BMC Public Health 2011; 11: 880.
15. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86: 1119-27.
16. Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res 2012; 14: 75-8.
17. New Zealand smoking cessation guidelines. Wellington, New Zealand: Ministry of Health; 2007.
18. West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. Psychopharmacology (Berl) 2004; 177: 195-9.
19. Bush K, Kivlahan D, McDonell M, Fihn S, Bradley K. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinkers. Arch Intern Med 1998; 158: 1789-95.
20. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav 2007; 32: 912-23.
21. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299-303.
22. Stead L, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. Cochrane Libr 2008; 3: CD000146.
23. Cepeda-Benito A, Reynoso JT, Erath S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J Consult Clin Psychol 2004; 72: 712-22.
24. Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res 2008; 10: 1245-50.
25. West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011; 365: 1193-200.
26. Li J, Grigg M. Changes in characteristics of New Zealand Quitline callers between 2001 and 2005. N Z Med J 2007; 120: U2584.
27. Bullen C, Howe C, Grigg M, et al. Recruitment into a cessation trial via the New Zealand Quitline: many benefits, few limitations. J Smoking Cessation 2008; 3: 30-4.
28. Li J. How do Quitline callers compare to the New Zealand smoking population? Wellington, New Zealand: The Quit Group, 2007.
29. Tobacco use in New Zealand: key findings from the 2009 New Zealand Tobacco Use Survey. Wellington, New Zealand: Ministry of Health, 2010 (http://www.health .govt .nz/publication/tobaccouse- new-zealand-key-findings-2009-nztobacco- use-survey).
30. Bullen C, Howe C, Lin RB, et al. Precessation nicotine replacement therapy: pragmatic randomized trial. Addiction 2010; 105: 1474-83.
31. Walker N, Howe C, Bullen C, et al. Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial. Addiction 2011; 106: 1176-85.
32. Walker N, Howe C, Bullen C, et al. The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support), on smoking cessation: a randomized controlled trial. Addiction 2012; 107: 1857-67.
33. Borland R, Segan CJ, Livingston PM, Owen N. The effectiveness of callback counselling for smoking cessation: a randomized trial. Addiction 2001; 96: 881-9.
34. Aubin H-J, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 63: 717-24.